Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Apr 06, 2020 01:19 PM IST | Source: PTI

Lupin launches generic drug used for prevention of organ rejection in kidney transplant in US

The company has launched the tablets in the strengths of 180 mg and 360 mg, Lupin said in a statement.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Lupin on Monday said it has launched generic Mycophenolic acid delayed-release tablets, which is used to prevent organ rejection in patients receiving kidney transplants in the US market.

The company has launched the tablets in the strengths of 180 mg and 360 mg, Lupin said in a statement.

Company's alliance partner Concord Biotech Ltd had received an approval from the United States Food and Drug Administration (USFDA) earlier for the product, it added.

Close

The tablets are generic version of Novartis Pharmaceuticals Corporation's Myfortic delayed-release tablets, 180 mg and 360 mg, Lupin said.

According to IQVIA MAT February 2020 data, Mycophenolic acid delayed-release tablets USP had an annual sales of around USD 156 million in the US, it added.

The tablets are indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant., Lupin said.

It is indicated for use in combination with cyclosporine and corticosteroids, it added.

Moneycontrol Ready Reckoner
Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.
Get best insights into Options Trading. Join the webinar by Mr. Vishal B Malkan on May 28 only on Moneycontrol. Register Now!

First Published on Apr 6, 2020 01:18 pm
Sections
Follow us on